Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide
Authors:Robert A Kloner|||Eric Stanek|||Christopher L Crowe|||Mukul Singhal|||Rebecca S Pepe|||Julia Bradsher|||Raymond C Rosen
Journal: The journal of sexual medicine
Publication Type: Observational Study
Date: 2023
DOI: 10.1093/jsxmed/qdac005
ID: 36897243
Affiliations:
Affiliations
Huntington Medical Research Institutes, Pasadena, CA, United States.|||HealthCore Inc., Wilmington, DE, United States.|||HealthCore Inc., Wilmington, DE, United States.|||HealthCore Inc., Wilmington, DE, United States.|||HealthCore Inc., Wilmington, DE, United States.|||Huntington Medical Research Institutes, Pasadena, CA, United States.|||Department of Psychiatry and Behavioral Sciences, School of Medicine, University of California, San Francisco, CA, United States.
Abstract
Treatment with phosphodiesterase type 5 inhibitors (PDE-5is) is effective in treating erectile dysfunction (ED).
